Compare Stocks → Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATRANASDAQ:AVRONASDAQ:CLLSNASDAQ:PRTONASDAQ:VCEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$0.69-2.8%$0.73$0.20▼$3.06$85.33M0.691.13 million shs828,693 shsAVROAVROBIO$1.24+1.6%$1.28$0.57▼$1.70$54.73M1.22159,806 shs36,515 shsCLLSCellectis$2.47+0.4%$2.66$0.96▼$3.77$136.74M3.1231,669 shs14,972 shsPRTOProteon Therapeutics$2.75+0.7%$19.37$0.22▼$3.94$60.99M0.61.11 million shs241,473 shsVCELVericel$43.86-5.2%$47.64$29.24▼$53.05$2.24B1.71433,923 shs426,930 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-3.25%-2.96%+1.30%+8.93%-76.79%AVROAVROBIO+1.64%-2.36%-1.59%-6.77%+33.33%CLLSCellectis+0.41%-11.79%+2.49%-8.18%+21.67%PRTOProteon Therapeutics+0.73%-11.00%-31.25%+28.50%-10.13%VCELVericel-5.19%-9.98%-3.88%+10.56%+39.64%AI “wealth window” is closing soon! (Ad)Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics3.8181 of 5 stars3.02.00.04.72.62.50.6AVROAVROBIO1.8429 of 5 stars3.03.00.00.02.81.70.6CLLSCellectis2.1862 of 5 stars3.52.00.00.01.12.51.3PRTOProteon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVCELVericel0.5936 of 5 stars1.51.00.00.02.80.81.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics2.00Hold$28.003,948.00% UpsideAVROAVROBIO2.00Hold$2.0061.29% UpsideCLLSCellectis3.00Buy$8.50244.13% UpsidePRTOProteon TherapeuticsN/AN/AN/AN/AVCELVericel3.00Buy$46.405.79% UpsideCurrent Analyst RatingsLatest ATRA, PRTO, VCEL, CLLS, and AVRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/1/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$51.00 ➝ $54.003/1/2024VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$46.00 ➝ $53.001/25/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$39.00 ➝ $51.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$8.57M9.63N/AN/A($0.97) per share-0.71AVROAVROBION/AN/A$0.29 per share4.26$2.13 per shareN/ACLLSCellectis$25.73M5.34N/AN/A$2.76 per share0.89PRTOProteon TherapeuticsN/AN/AN/AN/A($0.06) per shareN/AVCELVericel$197.52M10.74$0.02 per share2,625.13$4.73 per share9.27Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)AVROAVROBIO$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%5/9/2024 (Estimated)CLLSCellectis-$106.14M-$1.67N/AN/AN/A-346.65%-73.03%-32.22%5/2/2024 (Estimated)PRTOProteon Therapeutics-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/AVCELVericel-$3.18M-$0.09N/A87.72N/A-1.61%-1.55%-1.02%5/8/2024 (Estimated)Latest ATRA, PRTO, VCEL, CLLS, and AVRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023VCELVericel$0.18$0.26+$0.08$0.26$64.28 million$65.00 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.720.65AVROAVROBION/A15.7815.78CLLSCellectis0.572.202.20PRTOProteon TherapeuticsN/A5.985.98VCELVericelN/A4.494.21OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%AVROAVROBIO62.63%CLLSCellectis63.90%PRTOProteon Therapeutics23.03%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.50%AVROAVROBIO9.20%CLLSCellectis16.41%PRTOProteon Therapeutics45.70%VCELVericel5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableAVROAVROBIO1344.86 million40.73 millionOptionableCLLSCellectis23155.58 million46.46 millionOptionablePRTOProteon Therapeutics1722.18 millionN/ANot OptionableVCELVericel31448.38 million45.86 millionOptionableATRA, PRTO, VCEL, CLLS, and AVRO HeadlinesSourceHeadlineVericel Corpmoney.usnews.com - April 17 at 9:10 PMMutual of America Capital Management LLC Sells 21,706 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 15 at 5:51 AMVericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking Evenfinance.yahoo.com - April 13 at 1:24 PMVericel Co. (NASDAQ:VCEL) Sees Large Increase in Short Interestmarketbeat.com - April 12 at 10:31 AMVericel Co. (NASDAQ:VCEL) Shares Acquired by Conestoga Capital Advisors LLCmarketbeat.com - April 10 at 3:55 PMVericel Co. (NASDAQ:VCEL) Given Average Rating of "Buy" by Brokeragesmarketbeat.com - April 8 at 4:13 AMCommit To Buy Vericel At $25, Earn 9% Annualized Using Optionsnasdaq.com - April 7 at 10:47 PMVericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 3,278 Sharesinsidertrades.com - March 30 at 7:35 AMVericel Co. (NASDAQ:VCEL) Stock Holdings Decreased by SG Americas Securities LLCmarketbeat.com - March 30 at 4:17 AMVericel (NASDAQ:VCEL) Sets New 1-Year High at $51.40marketbeat.com - March 27 at 11:23 AMAnalyst Scoreboard: 5 Ratings For Vericelmarkets.businessinsider.com - March 27 at 1:54 AMTruist Financial Reaffirms "Buy" Rating for Vericel (NASDAQ:VCEL)marketbeat.com - March 26 at 9:35 AMVericel Co. (NASDAQ:VCEL) Shares Sold by Public Sector Pension Investment Boardmarketbeat.com - March 20 at 4:17 AMDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) Stockinsidertrades.com - March 17 at 5:42 AMVericel Co. (NASDAQ:VCEL) COO Sells $352,046.54 in Stockinsidertrades.com - March 14 at 9:39 AMVericel Co. (NASDAQ:VCEL) SVP Sells $367,852.95 in Stockinsidertrades.com - March 12 at 4:46 AMVCEL Oct 2024 50.000 callca.finance.yahoo.com - March 3 at 7:05 PMUS$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These Resultsfinance.yahoo.com - March 3 at 9:03 AMVericel Corporation (VCEL) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 2 at 7:12 PMVericel Full Year 2023 Earnings: EPS Beats Expectationsfinance.yahoo.com - March 2 at 8:15 AMBuy Rating Affirmed for Vericel on Strong Financials and Growth Prospectsmarkets.businessinsider.com - March 1 at 12:06 PMA Closer Look at 4 Analyst Recommendations For Vericelmarkets.businessinsider.com - March 1 at 12:06 PMVericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 12:06 PMVericel Corporation (NASDAQ:VCEL) Shares Could Be 48% Below Their Intrinsic Value Estimatefinance.yahoo.com - March 1 at 7:05 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAtara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.AVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.CellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Proteon TherapeuticsNASDAQ:PRTOProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.VericelNASDAQ:VCELVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.